➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
McKinsey
Moodys
Dow
Baxter

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Details for Patent: 7,241,907


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 7,241,907 protect, and when does it expire?

Patent 7,241,907 protects JEVTANA KIT and is included in one NDA.

Protection for JEVTANA KIT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-five patent family members in thirty-six countries.

Summary for Patent: 7,241,907
Title:Acetone solvate of dimethoxy docetaxel and its process of preparation
Abstract:This invention discloses and claims an acetone solvate of dimethoxydocetaxel or 4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1-hydroxy-7.beta.,10.beta.- -dimethoxy-9-oxotax-11-en-13.alpha.-yl (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate and its preparation by crystallization from an aqueous/acetone solution.
Inventor(s): Didier; Eric (Paris, FR), Perrin; Marc-Antoine (Jouy en Josas, FR)
Assignee: Aventis Pharma S.A. (Antony, FR)
Application Number:10/944,254
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,241,907
Patent Claim Types:
see list of patent claims
Compound; Use; Process;

Drugs Protected by US Patent 7,241,907

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;INTRAVENOUS 201023-001 Jun 17, 2010 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,241,907

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France03 11016Sep 19, 2003

International Family Members for US Patent 7,241,907

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 045667 ⤷  Free Forever Trial
Australia 2004274212 ⤷  Free Forever Trial
Brazil PI0414492 ⤷  Free Forever Trial
Canada 2539309 ⤷  Free Forever Trial
China 100429207 ⤷  Free Forever Trial
China 1849311 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Harvard Business School
AstraZeneca
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.